Develops innovative therapies for mitochondrial and neurodegenerative diseases
GenSight Biologics has raised €87M across 4 funding rounds from 6 investors, most recently a round in Jul 2025. Based in Paris, France; founded 2011; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-07-18 | Other | €500k | undisclosed investors | View deal → |
| 2017-09-14 | Other | €23M | — | View deal → |
| 2015-07-01 | Series B | €32M | Abingworth LLP,Fidelity,HealthCap,Index Ventures,Novartis Venture Fund | View deal → |
| 2013-04-01 | Series A | €32M | Abingworth LLP,Index Ventures,Novartis Venture Fund | View deal → |
